



COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING			
I hereby certify that this correspondence was deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: June 17, 2002.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	June 17, 2002

NOTIFICATION OF PRIOR SEQUENCE LISTING RECEIVED JUL 05 2002 Address to: Assistant Commissioner for Patents Washington, D.C. 20232 TECH CENTER 1600/2900	Attorney Docket	IRVN-007CON
	First Named Inventor	GRANGER, GALE A.
	Application Number	09/712,813
	Filing Date	November 13, 2000
	Confirmation Number	4642
	Group Art Unit	1646
	Examiner Name	MURPHY, JOSEPH F.
	Title:	"FACTORS AFFECTING TUMOR NECROSIS FACTOR RECEPTOR RELEASING ENZYME ACTIVITY, AND METHODS OF THE USE THEREOF"

Sir:

The above-identified patent application contains sequences of nucleic acid and polypeptides. A sequence listing was prepared for parent application, 09/081,385, filed 5/14/98, in paper and computer-readable format. The sequences in the present application are identical to those presented in the parent application. No new matter has been added. Therefore, please transfer to this application, in accordance with 37 CFR § 1.821(e), the fully compliant computer readable copy from applicants' other application.

Applicants respectfully submit that the present patent application is now in compliance with 37 CFR §§ 1.821 - 1.825. The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number IRVN-007CON.

Respectfully submitted,

Dated:

By:

Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



RECEIVED

JUL 05 2002

COPY OF PAPERS
ORIGINALLY FILED

TECH CENTER 1600/2900

Application No.: 0917281

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE